- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Concluding Thoughts on Ph+ ALL Treatment
Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease.
EP: 1.Overview of Characteristics Unique to Ph+ ALL
EP: 2.Timely Detection: Incidence and Prevalence of Ph+ ALL
EP: 3.Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life
EP: 4.Screening and Diagnosing of Ph+ ALL in Adults
EP: 5.Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management
EP: 6.Current Front-Line Targeted Treatments in Ph+ ALL
EP: 7.Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients
EP: 8.PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients
EP: 9.Value-Based Care Models Optimizing Ph+ ALL Patient Care
EP: 10.Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL
EP: 11.Disparities in Access to Care for Ph+ ALL patients
EP: 12.The Future of Ph+ ALL Treatments
EP: 13.Concluding Thoughts on Ph+ ALL Treatment
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.
In conclusion, Dr Abbas stressed engaging community practices more in Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) care while ensuring specialist leadership and optimal up-front therapy access. Dr Jabbour highlighted immense survival gains from 10% to 90% in recent years, with cures becoming reality now—not just ideals for the future. Equity in access to best available treatments remains vital. Dr McCloskey advised rethinking outdated potent toxicity perceptions given new safety data enabling more appropriate patient selection. Robust measurable residual disease monitoring must inform Ph+ ALL management everywhere. Dr Ebot-Tar discussed payers balancing innovation support, value demonstration to stakeholders, and personalized care. Ongoing collaboration between specialties and health plans can continue progress.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
